All In Biotech

Drug Trial Radar · NCT07870759

Efficacy and Safety of Combination Therapy Compared With Monotherapy in Patients With Benign Prostatic Hyperplasia

A Multicenter, Randomized, Double-Blind, Phase III Clinical Trial to Compare the Efficacy and Safety of UROCOM-R1 Plus UROCOM-R2 Combination Therapy Versus UROCOM-R1 or UROCOM-R2 Monotherapy in Patients With Benign Prostatic Hyperplasia

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 660 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

660

Planned (sponsor's estimate)

Start

Nov 9, 2026

Primary completion

Aug 31, 2027

Study completion Aug 31, 2027

Sponsor

Lead sponsor
Il-Yang Pharm. Co., Ltd.Industry
Sponsor type
Industry
First posted
Oct 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Efficacy and Safety of Combination Therapy Compared With Monotherapy in Patients With Benign Prostatic Hyperplasia

Conditions

  • Benign Prostatic Hyperplasia

Interventions

  • Finasteride 5 mg Tablet, single doseDrug

    Finasteride 5mg administered orally once daily

  • Tamsulosin 0.4Mg CapsuleDrug

    Tamsulosin 0.4mg capsule administered orally once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total IPSSTime frame: Baseline to week 48

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.